Skip to main content
Equibles
TRDA logo

TRDA · Entrada Therapeutics, Inc. · Financials

Track TRDA — free

Use TRDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.80 +0.38 (+5.92%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$264.77M
Shares
38.94M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
$25.42M -87.9%
FY2025 Revenue FY2023–FY2025
Net Income
-$143.75M -319%
FY2025 Net Income FY2020–FY2025
Operating Margin
-621.13% -643.4pp
FY2025 Operating Margin FY2023–FY2025
Diluted EPS
-$3.47 -306.5%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$128.51M -209.2%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$4.69M $25.42M $210.78M $129.01M — — —
$140.74M $142.27M $125.31M $99.88M $66.61M $35.93M $21.1M
$40.47M $41.05M $38.47M $32.29M $30.64M $15.2M $5.57M
$181.21M $183.32M $163.77M $132.18M $97.25M $51.13M $26.67M
-$176.53M -$157.9M $47.01M -$3.16M -$97.25M -$51.13M -$26.67M
— -621.13% 22.3% -2.45% — — —
$11.57M $15.07M $19.47M $15.22M $2.63M -$31K $144K
$819K $924K $859K $18.74M $0 $0 $0
-$165.78M -$143.75M $65.63M -$6.69M -$94.62M -$51.16M -$26.52M
— -565.48% 31.13% -5.18% — — —
-$166.11M -$143.06M $65.39M -$4.43M -$96.67M -$51.16M —
USD/shares -$3.97 -$3.47 $1.76 -$0.20 -$3.02 -$8.16 -$24.00
USD/shares -$3.97 -$3.47 $1.68 -$0.20 -$3.02 -$8.16 -$24.00
shares — 41.37M 37.31M 33.05M 31.29M 6.27M 1.11M
shares — 41.37M 39M 33.05M 31.29M 6.27M 1.11M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 5.49×
EV/EBIT
—
Peer median 8.97×
P/E (TTM)
—
Peer median 11.00×

Peer medians compare against the 315 similar-size Biotechnology companies (of 536 listed).

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023
Reportable Segment $25,421,000 $210,782,000 $129,013,000
Key facts CIK 1689375 CUSIP 29384C108 13F (30d) 52 filings 52 filers Visit website Investor relations